Meeder Asset Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Meeder Asset Management’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-353	Closed	-$23K	–	2531
2021 Q3	$23K	Sell	353 -2,019	-85%	-$144K	﹤0.01%	1377
2021 Q2	$185K	Buy	2,372 +150	+7%	+$11.1K	0.01%	750
2021 Q1	$210K	Buy	+2,222	New	+$264K	0.01%	712
2020 Q4	–	Sell	-1,574	Closed	-$138K	–	2362
2020 Q3	$138K	Buy	1,574 +802	+104%	+$55.9K	0.01%	702
2020 Q2	$51K	Buy	+772	New	+$44.5K	﹤0.01%	919

Other funds holding TPTX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Meeder Asset Management's TPTX Position: Q4 2021 in Review

Meeder Asset Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q4 2021, closing a stake of 353 shares — an estimated $23K sold.

Meeder Asset Management first reported a position in TPTX in Q2 2020 and held it in 5 quarters. The position peaked at $210K in Q1 2021. 172 funds tracked by Wall St. Rank hold TPTX as of Q4 2021.

Meeder Asset Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Meeder Asset Management sold 353 Turning Point Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $23K.
Meeder Asset Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2020 and held it in 5 quarters.
Meeder Asset Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $210K in Q1 2021.
172 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Meeder Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.